CliffBio
small molecule

CARMUSTINE

CARMUSTINE

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameCARMUSTINE
Active ingredientCARMUSTINE
Strength100MG/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalOctober 2023
Marketing statusRX

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.